- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 17, 2023
Highlights
- Market Cap
- $41.48B
- Enterprise Value
- $41.21B
- EPS (TTM)
- -$7.13
- Gross Profit (TTM)
- -$4.70M
- EBITDA (TTM)
- -$1.34B
- Year Range
- $0.16 - $10.12
- ROA (TTM)
- -60.86%
- ROE (TTM)
- -91.45%
- Avg. Volume (1M)
- 22K
- Avg. Volume Value (1M)
- $204.24K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RVMDW Performance Chart
Revolution Medicines Inc. Warrant (RVMDW) is up 917.7% since the beginning of the year. At $10 per share, RVMDW is trading 5.5% below its 52-week high of $10.
Loading charts...
Compare this symbol against anything
Returns By Period
Revolution Medicines Inc. Warrant (RVMDW) has returned 917.66% so far this year and 3,885.42% over the past 12 months.
Revolution Medicines Inc. Warrant
- 1D
- -3.19%
- 1M
- 0.16%
- 6M
- 517.10%
- YTD
- 917.66%
- 1Y
- 3,885.42%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 130.63%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
RVMDW Monthly Returns History
Based on dividend-adjusted daily data since Nov 17, 2023, RVMDW's average daily return is +1.94%, while the average monthly return is +23.48%. At this rate, an investment would double in approximately 0.3 years.
Historically, 58% of months were positive and 42% were negative. The best month was Apr 2026 with a return of +181.0%, while the worst month was Mar 2025 at -55.8%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, RVMDW closed higher 44% of trading days. The best single day was May 23, 2025 with a return of +153.5%, while the worst single day was May 27, 2025 at -50.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 64.91% | 39.35% | -17.13% | 181.01% | 23.86% | 50.56% | 1.97% | 917.66% | |||||
| 2025 | -13.50% | -44.77% | -55.81% | 131.84% | 19.98% | 148.53% | -19.03% | -22.38% | 81.65% | 16.71% | 145.71% | 9.29% | 422.17% |
| 2024 | -45.45% | 27.22% | -20.31% | 102.68% | -55.10% | -38.53% | 46.91% | -46.67% | 75.00% | 42.86% | 77.65% | -49.34% | -45.45% |
| 2023 | -45.00% | -40.00% | -67.00% |
Benchmark Metrics
Revolution Medicines Inc. Warrant has an annualized alpha of 8457.58%, beta of 1.85, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 17, 2023.
- This stock captured 330.63% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -338.77%) - a profile typical of hedging or uncorrelated assets.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 8,457.58%
- Beta
- 1.85
- R²
- 0.01
- Upside Capture
- 330.63%
- Downside Capture
- -338.77%
Return for Risk
Risk / Return Rank
RVMDW ranks 100 for risk / return — above 100% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Revolution Medicines Inc. Warrant (RVMDW) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RVMDW | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +17.70 | ||
| Sortino ratioReturn per unit of downside risk | +4.72 | ||
| Omega ratioGain probability vs. loss probability | 1.87 | 1.25 | +0.61 |
| Calmar ratioReturn relative to maximum drawdown | 74.87 | 2.00 | +72.86 |
| Martin ratioReturn relative to average drawdown | 171.25 | 8.49 | +162.76 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Revolution Medicines Inc. Warrant. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Revolution Medicines Inc. Warrant was 96.90%, occurring on Apr 10, 2025. Recovery took 186 trading sessions.
The current Revolution Medicines Inc. Warrant drawdown is 3.58%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.90%Apr 2025 | 1y 4mo | 9mo 2d | 2y 1moNov 2023 - Jan 2026 | 2025 selloff2025 |
-59.65%Feb 2026 | 18d | 2mo 9d | 2mo 27dJan 2026 - Apr 2026 | — |
-31.43%Apr 2026 | 11d | 29d | 1mo 10dApr 2026 - May 2026 | — |
-26.96%Jun 2026 | 8d | 12d | 20dJun 2026 - Jun 2026 | — |
-15.17%Jul 2026 | 16d | — | 1mo 4dJun 2026 - now | — |
Drawdown Indicators
| RVMDW | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.90% | -56.78% | -40.12% |
Max Drawdown (1Y)Largest decline over 1 year | -59.65% | -9.10% | -50.55% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -3.58% | -1.58% | -2.00% |
Average DrawdownAverage peak-to-trough decline | -63.64% | -10.70% | -52.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.03% | 2.14% | +23.89% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Revolution Medicines Inc. Warrant over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Revolution Medicines Inc. Warrant is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RVMDW in comparison with other companies in the Biotechnology industry. Currently, RVMDW has a P/B value of 1.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RVMDW
Add Revolution Medicines Inc. Warrant to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RVMDW